Dasatinib Drugs Market Report 2026

Dasatinib Drugs Market Overview

• Dasatinib Drugs market size has reached to $1.53 billion in 2025 • Expected to grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Rising Prevalence Of Chronic Myeloid Leukemia (CML) Fuels Growth Of Dasatinib Drugs Market • Market Trend: Generic Dasatinib Boosting Competition And Accessibility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Dasatinib Drugs Market?

Dasatinib drugs refer to a type of targeted therapy known as tyrosine kinase inhibitors, primarily used to treat blood cancers, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). They work by blocking proteins that drive cancer cell growth, helping to slow disease progression. This leads to improved survival rates and better management of the disease. The main types of products in the dasatinib drugs market are tablets, oral suspension, and others. Dasatinib is primarily available in tablet form, which makes it convenient for patients to take orally. The various indications include chronic myeloid leukemia, acute lymphoblastic leukemia, and others, and several end users including hospitals, specialty clinics, and home healthcare.

What Is The Dasatinib Drugs Market Growth Forecast?

The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in leukemia patient population, rising demand for personalized cancer treatment, increased penetration of generic oncology drugs, expansion of home-based cancer care, advancements in targeted drug development. Major trends in the forecast period include rising adoption of targeted cancer therapies, increasing use of oral oncology drugs, growing demand for generic dasatinib products, expansion of combination therapy approaches, improved patient adherence through oral formulations.

Global Dasatinib Drugs Market Segmentation

1) By Product Type: Tablets, Oral Suspension, Other Products 2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications 3) By End User: Hospitals, Specialty Clinics, Home Healthcare Subsegments: 1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets 2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension 3) By Other Products: Combination Therapies, Generic Dasatinib Products

What Is The Driver Of The Dasatinib Drugs Market?

The increasing prevalence of chronic myeloid leukemia (CML) is expected to propel the growth of the dasatinib drug market going forward. Chronic myeloid leukemia (CML) is a cancer of the bone marrow and blood characterized by uncontrolled growth of abnormal white blood cells. The rising prevalence of CML is driven by increasing environmental exposures and lifestyle-related risk factors. The dasatinib drug market supports disease management by inhibiting the BCR-ABL tyrosine kinase protein responsible for the uncontrolled proliferation of leukemic cells. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based cancer-focused health organization, CML cases in the United States increased to 8,930 in 2023, up from 8,860 cases in 2022. Therefore, the increasing prevalence of chronic myeloid leukemia (CML) is driving the growth of the dasatinib drug industry.

Key Players In The Global Dasatinib Drugs Market

Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Hetero Drugs Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Lupin Limited, MSN Laboratories Pvt. Ltd., Hikma Pharmaceuticals plc, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

Global Dasatinib Drugs Market Trends and Insights

Major companies operating in the dasatinib drugs market are focusing on developing generic drugs to expand market reach, offer cost-effective treatment alternatives, and improve accessibility for patients requiring long-term cancer therapy. Generic dasatinib medicines refer to therapeutically equivalent formulations of the branded drug that deliver the same active ingredient, strength, quality, and clinical efficacy at a lower cost, thereby increasing affordability, promoting competition, and reducing the financial burden on patients and healthcare systems. For instance, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, launched the first generic version of Sprycel (dasatinib) in the United States for treating certain types of leukemia in adults and children, offering a high-quality, lower-cost alternative that enhances treatment access and supports competitive pricing within the dasatinib drugs market.

What Are Latest Mergers And Acquisitions In The Dasatinib Drugs Market?

In January 2025, Handa Therapeutics, a US-based healthcare technology company, acquired PHYRAGO (dasatinib) tablets, an FDA-approved treatment for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, from Nanocopoeia, LLC, for an undisclosed amount. With this acquisition, Handa Therapeutics aims to strengthen its oncology portfolio and expand its presence in the chronic myeloid leukemia (CML) therapeutics market. Nanocopoeia, LLC, is a US-based biopharmaceutical company that specializes in developing and manufacturing a specific formulation of the dasatinib drug.

Regional Insights

North America was the largest region in the dasatinib drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Dasatinib Drugs Market?

The dasatinib drugs market consists of sales of sprycel and generic dasatinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dasatinib Drugs Market Report 2026?

The dasatinib drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dasatinib drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.